MedTrace Logo

Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy

NCT07329920 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-01-12

No results posted yet for this study

Summary

The aim of this study was to evaluate the clinical utility of mesenchymal CTC ratio dynamics as a real-time biomarker for PDAC patients with neoadjuvant therapy.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Circulating Tumor Cells (CTCs)
  • Neoadjuvant Therapy

Interventions

PROCEDURE

surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines

Retrospective studies do not require intervention measures.

Sponsors & Collaborators

  • Guo ShiWei

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-10
Primary Completion
2021-09-15
Completion
2025-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07329920 on ClinicalTrials.gov